North America Pain Management Market - 2024-2033
The North America Pain Management Market was valued at US$ 25.85 billion in 2024 and is anticipated to reach US$ 46.87 billion by 2033, at a CAGR of 0.069 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the North America Pain Management Market.
This report delivers a comprehensive overview of the North America Pain Management Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding North America Pain Management Market. The North America Pain Management Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
North America Pain Management Market Scope:
Key Players
This report delivers a comprehensive overview of the North America Pain Management Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding North America Pain Management Market. The North America Pain Management Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the North America Pain Management Market.
This report delivers a comprehensive overview of the North America Pain Management Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding North America Pain Management Market. The North America Pain Management Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
North America Pain Management Market Scope:
Key Players
- Bayer AG
- Kenvue
- Teva Pharmaceuticals Industries Ltd.
- Viatris Inc.
- Pfizer Inc
- Purdue Pharmaceuticals L.P
- Abbott
- Collegium Pharmaceutical, Inc.
- Sun Pharmaceutical Industries Ltd.
- Virpax Pharmaceuticals
This report delivers a comprehensive overview of the North America Pain Management Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding North America Pain Management Market. The North America Pain Management Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY DRUG TYPE
4.1. Snippet by Indication
4.2. Snippet by Mode of Prescription
4.3. Snippet by Distribution Channel
5. DYNAMICS
5.1. Impacting Factors
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Chronic Pain Conditions
5.1.1.2. Rising Development of Novel Drugs
5.1.1.3. XX
5.1.2. Restraints
5.1.2.1. Side Effects Associated with the Drugs
5.1.2.2. Competition from Alternative Pain Management Treatments
5.1.2.3. XX
5.1.3. Opportunity
5.1.3.1. Development of Non-Opioid Alternatives
5.1.3.2. XX
5.1.4. Impact Analysis
6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
6.1. Market Leaders and Pioneers
6.1.1. Emerging Pioneers and Prominent Players
6.1.2. Established leaders with largest selling Brand
6.1.3. Market leaders with established Product
6.2. CXO Perspectives
6.3. Latest Developments and Breakthroughs
6.4. Case Studies/Ongoing Research
6.5. North America Regulatory and Reimbursement Landscape
6.6. Porter’s Five Force Analysis
6.7. Supply Chain Analysis
6.8. Patent Analysis
6.9. SWOT Analysis
6.10. Unmet Needs and Gaps
6.11. Recommended Strategies for Market Entry and Expansion
6.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
6.13. Pricing Analysis and Price Dynamics
6.14. Key Opinion Leaders
7. PAIN MANAGEMENT MARKET, BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Non-Steroidal Anti-Inflammatory Drugs*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Acetaminophen
7.2.4. Ibuprofen
7.2.5. Naproxen
7.2.6. Diclofenac
7.2.7. Aspirin
7.2.8. Celecoxib
7.2.9. Others
7.3. Opioids
7.3.1. Oxycodone
7.3.2. Fentanyl
7.3.3. Hydrocodone
7.3.4. Morphine
7.3.5. Codeine
7.3.6. Others
7.4. Corticosteroids
7.4.1. Prednisone
7.4.2. Dexamethasone
7.4.3. Prednisolone
7.4.4. Others
7.5. Muscle Relaxants
7.6. Anticonvulsant Drugs
7.7. Others
8. PAIN MANAGEMENT MARKET, BY INDICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Arthritis Pain*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Back Pain
8.4. Surgery Pain
8.5. Headaches & Migraine
8.6. Injury Pain
8.7. Cancer Pain
8.8. Fibromyalgia
8.9. Muscle Spasms
8.10. Menstrual Pain
8.11. Neuropathic Pain
8.12. Others
9. PAIN MANAGEMENT MARKET, BY MODE OF PRESCRIPTION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
9.1.2. Market Attractiveness Index, By Mode of Prescription
9.2. Prescription Based*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Over-the-Counter
10. PAIN MANAGEMENT MARKET, BY DISTRIBUTION CHANNEL
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Retail Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Hospital Pharmacies
10.4. Clinics
10.5. Online Pharmacies
10.6. Others
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11.1. Competitive Overview and Key Market Players
11.1.1. Market Share Analysis and Positioning Matrix
11.1.2. Strategic Partnerships, Mergers & Acquisitions
11.1.3. Key Developments in Product Portfolios and Innovations
11.1.4. Company Benchmarking
12. COMPANY PROFILES
12.1. Bayer AG*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.2.3. Historic and Forecasted Product Sales
12.1.2.4. Product Sales Volume
12.1.3. Financial Overview
12.1.4. Company Revenue
12.1.4.1. Geographical Revenue Shares
12.1.4.1.1. Revenue Forecasts
12.1.4.2. Key Developments
12.1.4.2.1. Mergers & Acquisitions
12.1.4.2.2. Key Product Development Activities
12.1.4.2.3. Regulatory Approvals, etc.
12.1.4.3. SWOT Analysis
12.2. Kenvue
12.3. Teva Pharmaceuticals Industries Ltd.
12.4. Viatris Inc.
12.5. Pfizer Inc
12.6. Purdue Pharmaceuticals L.P
12.7. Abbott
12.8. Collegium Pharmaceutical, Inc.
12.9. Sun Pharmaceutical Industries Ltd.
12.10. Virpax Pharmaceuticals (LIST NOT EXHAUSTIVE)
13. ASSUMPTION AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY DRUG TYPE
4.1. Snippet by Indication
4.2. Snippet by Mode of Prescription
4.3. Snippet by Distribution Channel
5. DYNAMICS
5.1. Impacting Factors
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Chronic Pain Conditions
5.1.1.2. Rising Development of Novel Drugs
5.1.1.3. XX
5.1.2. Restraints
5.1.2.1. Side Effects Associated with the Drugs
5.1.2.2. Competition from Alternative Pain Management Treatments
5.1.2.3. XX
5.1.3. Opportunity
5.1.3.1. Development of Non-Opioid Alternatives
5.1.3.2. XX
5.1.4. Impact Analysis
6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
6.1. Market Leaders and Pioneers
6.1.1. Emerging Pioneers and Prominent Players
6.1.2. Established leaders with largest selling Brand
6.1.3. Market leaders with established Product
6.2. CXO Perspectives
6.3. Latest Developments and Breakthroughs
6.4. Case Studies/Ongoing Research
6.5. North America Regulatory and Reimbursement Landscape
6.6. Porter’s Five Force Analysis
6.7. Supply Chain Analysis
6.8. Patent Analysis
6.9. SWOT Analysis
6.10. Unmet Needs and Gaps
6.11. Recommended Strategies for Market Entry and Expansion
6.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
6.13. Pricing Analysis and Price Dynamics
6.14. Key Opinion Leaders
7. PAIN MANAGEMENT MARKET, BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Non-Steroidal Anti-Inflammatory Drugs*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Acetaminophen
7.2.4. Ibuprofen
7.2.5. Naproxen
7.2.6. Diclofenac
7.2.7. Aspirin
7.2.8. Celecoxib
7.2.9. Others
7.3. Opioids
7.3.1. Oxycodone
7.3.2. Fentanyl
7.3.3. Hydrocodone
7.3.4. Morphine
7.3.5. Codeine
7.3.6. Others
7.4. Corticosteroids
7.4.1. Prednisone
7.4.2. Dexamethasone
7.4.3. Prednisolone
7.4.4. Others
7.5. Muscle Relaxants
7.6. Anticonvulsant Drugs
7.7. Others
8. PAIN MANAGEMENT MARKET, BY INDICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Arthritis Pain*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Back Pain
8.4. Surgery Pain
8.5. Headaches & Migraine
8.6. Injury Pain
8.7. Cancer Pain
8.8. Fibromyalgia
8.9. Muscle Spasms
8.10. Menstrual Pain
8.11. Neuropathic Pain
8.12. Others
9. PAIN MANAGEMENT MARKET, BY MODE OF PRESCRIPTION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
9.1.2. Market Attractiveness Index, By Mode of Prescription
9.2. Prescription Based*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Over-the-Counter
10. PAIN MANAGEMENT MARKET, BY DISTRIBUTION CHANNEL
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Retail Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Hospital Pharmacies
10.4. Clinics
10.5. Online Pharmacies
10.6. Others
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11.1. Competitive Overview and Key Market Players
11.1.1. Market Share Analysis and Positioning Matrix
11.1.2. Strategic Partnerships, Mergers & Acquisitions
11.1.3. Key Developments in Product Portfolios and Innovations
11.1.4. Company Benchmarking
12. COMPANY PROFILES
12.1. Bayer AG*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.2.3. Historic and Forecasted Product Sales
12.1.2.4. Product Sales Volume
12.1.3. Financial Overview
12.1.4. Company Revenue
12.1.4.1. Geographical Revenue Shares
12.1.4.1.1. Revenue Forecasts
12.1.4.2. Key Developments
12.1.4.2.1. Mergers & Acquisitions
12.1.4.2.2. Key Product Development Activities
12.1.4.2.3. Regulatory Approvals, etc.
12.1.4.3. SWOT Analysis
12.2. Kenvue
12.3. Teva Pharmaceuticals Industries Ltd.
12.4. Viatris Inc.
12.5. Pfizer Inc
12.6. Purdue Pharmaceuticals L.P
12.7. Abbott
12.8. Collegium Pharmaceutical, Inc.
12.9. Sun Pharmaceutical Industries Ltd.
12.10. Virpax Pharmaceuticals (LIST NOT EXHAUSTIVE)
13. ASSUMPTION AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
